S100A9 and systemic lupus erythematosus: In fact, there are ongoing clinical trials in SLE performed by us using a quinoline-3-carboxamide compound targeting S100A9 which will give us more information on the role of S100A9 blockade in SLE and if it can be used as a therapeutic target.